Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.

Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs CS.

J Immunother Cancer. 2019 May 3;7(1):119. doi: 10.1186/s40425-019-0603-3.

2.

Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.

Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT.

JCI Insight. 2019 Apr 4;4(7). pii: 126853. doi: 10.1172/jci.insight.126853. eCollection 2019 Apr 4.

3.

Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer.

Saleh AD, Cheng H, Martin SE, Si H, Ormanoglu P, Carlson S, Clavijo PE, Yang X, Das R, Cornelius S, Couper J, Chepeha D, Danilova L, Harris TM, Prystowsky MB, Childs GJ, Smith RV, Robertson AG, Jones SJM, Cherniack AD, Kim SS, Rait A, Pirollo KF, Chang EH, Chen Z, Van Waes C.

Clin Cancer Res. 2019 May 1;25(9):2860-2873. doi: 10.1158/1078-0432.CCR-18-0716. Epub 2019 Feb 5.

PMID:
30723145
4.

Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors.

Nagaya T, Friedman J, Maruoka Y, Ogata F, Okuyama S, Clavijo PE, Choyke PL, Allen C, Kobayashi H.

Cancer Immunol Res. 2019 Mar;7(3):401-413. doi: 10.1158/2326-6066.CIR-18-0546. Epub 2019 Jan 25.

PMID:
30683733
5.

Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.

Clavijo PE, Friedman J, Robbins Y, Moore EC, Smith E, Zauderer M, Evans EE, Allen CT.

Cancer Immunol Res. 2019 Feb;7(2):282-291. doi: 10.1158/2326-6066.CIR-18-0156. Epub 2018 Dec 4.

PMID:
30514791
6.

Lymphotoxin-β receptor-NIK signaling induces alternative RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer.

Das R, Coupar J, Clavijo PE, Saleh A, Cheng TF, Yang X, Chen J, Van Waes C, Chen Z.

Mol Carcinog. 2019 Mar;58(3):411-425. doi: 10.1002/mc.22938. Epub 2018 Nov 28.

PMID:
30488488
7.

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.

Hicks KC, Fantini M, Donahue RN, Schwab A, Knudson KM, Tritsch SR, Jochems C, Clavijo PE, Allen CT, Hodge JW, Tsang KY, Schlom J, Gameiro SR.

Oncoimmunology. 2018 Jul 30;7(11):e1466018. doi: 10.1080/2162402X.2018.1466018. eCollection 2018.

8.

WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Sun L, Moore E, Berman R, Clavijo PE, Saleh A, Chen Z, Van Waes C, Davies J, Friedman J, Allen CT.

Oncoimmunology. 2018 Jul 23;7(10):e1488359. doi: 10.1080/2162402X.2018.1488359. eCollection 2018.

9.

Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers.

Zhang J, Chen T, Yang X, Cheng H, Späth SS, Clavijo PE, Chen J, Silvin C, Issaeva N, Su X, Yarbrough WG, Annunziata CM, Chen Z, Van Waes C.

Cancer Res. 2018 Aug 15;78(16):4613-4626. doi: 10.1158/0008-5472.CAN-17-0642. Epub 2018 Jun 19.

10.

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms.

Moore EC, Sun L, Clavijo PE, Friedman J, Harford JB, Saleh AD, Van Waes C, Chang EH, Allen CT.

Oncoimmunology. 2018 May 7;7(7):e1404216. doi: 10.1080/2162402X.2017.1404216. eCollection 2018. Erratum in: Oncoimmunology. 2018 Dec 13;8(2):e1534569.

11.

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation.

Morisada M, Clavijo PE, Moore E, Sun L, Chamberlin M, Van Waes C, Hodge JW, Mitchell JB, Friedman J, Allen CT.

Oncoimmunology. 2017 Nov 27;7(3):e1395996. doi: 10.1080/2162402X.2017.1395996. eCollection 2018.

12.

Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells.

Clavijo PE, Moore EC, Chen J, Davis RJ, Friedman J, Kim Y, Van Waes C, Chen Z, Allen CT.

Oncotarget. 2017 Jun 11;8(34):55804-55820. doi: 10.18632/oncotarget.18437. eCollection 2017 Aug 22.

13.

Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.

Davis RJ, Moore EC, Clavijo PE, Friedman J, Cash H, Chen Z, Silvin C, Van Waes C, Allen C.

Cancer Res. 2017 May 15;77(10):2607-2619. doi: 10.1158/0008-5472.CAN-16-2534. Epub 2017 Mar 31.

14.

Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade.

Moore E, Clavijo PE, Davis R, Cash H, Van Waes C, Kim Y, Allen C.

Cancer Immunol Res. 2016 Dec;4(12):1061-1071. Epub 2016 Nov 7.

15.

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.

Allen CT, Clavijo PE, Van Waes C, Chen Z.

Cancers (Basel). 2015 Dec 9;7(4):2397-414. doi: 10.3390/cancers7040900. Review.

16.

Anergic CD8+ T lymphocytes have impaired NF-κB activation with defects in p65 phosphorylation and acetylation.

Clavijo PE, Frauwirth KA.

J Immunol. 2012 Feb 1;188(3):1213-21. doi: 10.4049/jimmunol.1100793. Epub 2011 Dec 28.

Supplemental Content

Loading ...
Support Center